Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avricore Health Inc V.AVCR

Alternate Symbol(s):  AVCRF

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.


TSXV:AVCR - Post by User

Bullboard Posts
Post by kingposton Apr 25, 2016 8:55pm
332 Views
Post# 24808582

trajectory bodes well for possible multiples valued at...

trajectory bodes well for possible multiples valued at...In general when the growth rate of a company equals the P/E multiple most analysts consider those stocks as good buys .... this is just in general of course.....This means that a company with a 10% growth rate should trade with a  P/E multiple of 10 but a company growing at 100% should trade at 100 to 1 PE ... So the same company can be worth 10 times more just based on their internal growth rate being 100% instead of 10%... This obviously is a huge difference and shows how valuable high growth is...and this is the norm  on both Wall st and Bay street among fundamental financial analysts...
For start ups since they generally do not typically get earning for several years, this same generally methodology is applyed but instead using  the growth in sales as a proxy for earnings growth , in the interim, .. Another aspect is that after break even it is more common that earnings grow faster than sales, since fixed costs are spread out among a larger level of sales, and so fixed costs per unit of sales is lower and lower as sales increase... and causing earnings to rise faster than sales....
With this as a backdrop I like what I am seeing with the initial sales trajectory here...and the inferred possible valuation...
Bullboard Posts